In phase 3 DREAM3R, first-line Imfinzi plus chemotherapy showed survival and response benefits in advanced mesothelioma, but results were inconclusive.
Positive results for Hernexeos (zongertinib) as a first-line treatment for non-small cell lung cancer (NSCLC) with HER2 mutations were reported yesterday at the European Society for Medical Oncology ...
Final Phase 2 data show casdozokitug with atezolizumab/bevacizumab achieves a 17.2% complete response rate in HCC patients. Coherus BioSciences, Inc. announced ...
SYDNEY, July 14, 2025 /PRNewswire/ -- Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, is pleased to announce exciting new data from its Phase 1b clinical trial evaluating ...
AI-guided, synthetic lethal therapy achieves complete metabolic response after just two cycles in patient who failed three prior state-of-the-art treatment regimens. Complete response in an aggressive ...
CureVac says set to launch trial with 30,000 volunteers Says immune response triggered in Phase I trial Chooses highest dosage of 12 micrograms for Phase III Says CVnCoV vaccine generally well ...
Primary Endpoint met: Statistically significant reduction in blood-fat levels after eating (-51.9%) Multiple secondary endpoints met: Including statistically significant reduction in weight regain ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback